On April 7, 2026, Route 92 Medical, a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced a $50 million growth financing led by Novo Holdings. New investor Sectoral Asset Management and existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group joined in the financing round. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction.

The Wilson Sonsini team that advised Novo Holdings on the transaction included Danielle Naftulin, Tamara Labanowski, and Emily Gottfredson.

For more information, please see Route 92 Medical’s news release and Novo Holdings’ news release. Additional coverage can be found on Medical Device Network.